Acadia Pharmaceuticals Gets Preliminary Court Approval for Derivative Settlement

What Happened

• Acadia Pharmaceuticals announced that on August 24, 2026 the U.S. District Court for the Southern District of California preliminarily approved a proposed settlement in the stockholder derivative action Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB.
• Under the court order, Acadia must publish a Notice of Pendency and Proposed Settlement of Derivative Matters and has filed the Stipulation and Agreement of Settlement; both documents are posted on the company’s Investor Relations site.

Key Details

• Court: U.S. District Court, Southern District of California; preliminary approval date: August 24, 2026.
• Case: Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB.
• Documents: Notice of Pendency and Proposed Settlement (Exhibit 99.1) and Stipulation and Agreement of Settlement (Exhibit 99.2) are available at ir.acadia.com.
• Filing: Reported in Form 8-K under Item 8.01 (Other Events).

Why It Matters

• The preliminary approval signals the lawsuit may be resolved without further protracted litigation, which can limit ongoing legal costs and management distraction.
• Investors should review the posted Notice and Stipulation for settlement terms and watch for any final approval hearing or further disclosures that could affect the company’s obligations or financials.